From Investing.com:



This article covers the latest Wall Street analysis of Eli Lilly and Company, a biopharmaceutical company with a strong focus on diabetes, obesity, Alzheimer’s, and oncology treatments. The company’s strategic focus and potential growth in its diabetes portfolio, particularly its GLP-1 treatments Mounjaro and Zepbound, have garnered positive attention from Wall Street analysts. The article includes insights into the company’s market performance, regulatory environment, stock performance, potential impacts of external factors, and upcoming product launches.

Positive points highlighted in the article include Eli Lilly’s strategic acquisitions and focus on gene editing technology, its strong position in the diabetes market, and its potential for future growth in the fields of diabetes, oncology, and Alzheimer’s treatments. The article also addresses potential challenges and threats for Eli Lilly, such as slowing momentum in the GLP-1 drug class, regulatory hurdles, and supply chain issues.

Overall, the article provides a comprehensive overview of Eli Lilly’s position in the biopharmaceutical industry and presents insights for potential investors to consider.

The company’s revenue for the last twelve months as of Q3 2023 reached $32.07 billion, marking a growth rate of 9.69%. Additionally, Eli Lilly’s return on invested capital and a P/E ratio (adjusted for the last twelve months as of Q3 2023) of 64.71 are highlighted, offering a data-driven perspective on the stock’s valuation for potential investors. The article also mentions a special Cyber Monday sale for InvestingPro subscription, offering a discount of up to 60%.



Original: Wall Street takes on Eli Lilly’s prospects By Investing.com